-- 第一季度GDP初步估计值显示，继上一季度增长0.5%之后，第二季度增长2.0%；其中，个人支出增长1.6%，上一季度增长1.9%。 非住宅固定投资、库存增长和政府支出对GDP增长做出了积极贡献，但部分被住宅固定投资和净出口的负面影响所抵消。 GDP价格指数上涨3.6%，上一季度增长3.7%。个人消费支出（PCE）价格指数和核心PCE价格均较第四季度有所加速上涨。 亚特兰大联邦储备银行对第二季度GDP的初步预测为增长3.7%。 3月份个人收入增长0.6%，2月份基本持平；3月份个人消费支出增长0.9%，上一季度增长0.6%。 经调整个人消费支出（PCE）价格指数0.7%的涨幅后，3月份实际消费增长0.2%，2月份增幅为0.3%。整体价格指数同比涨幅从2.8%跃升至3.5%。 核心PCE价格指数环比上涨0.3%，此前一季度上涨0.4%，同比涨幅从3.0%加速至3.2%。 第一季度就业成本指数环比上涨0.9%，此前一季度上涨0.7%，反映出工资和福利增长速度加快。 芝加哥制造业采购经理人指数（PMI）4月份从3月份的52.8降至49.2，这是本月最后一次公布的地区制造业数据。ISM全国制造业PMI将于周五公布。 截至4月25日当周，首次申请失业救济人数减少2.6万人，至18.9万人，为50多年来的最低水平，四周移动平均值也因此下降3500人，至20.75万人。 截至4月18日当周，就业调查数据显示，投保申请人数减少2.3万人，至178.5万人。而截至3月14日当周，投保申请人数为181.6万人。 受建筑许可、商业预期和股价等负面因素的影响，世界大型企业联合会（Conference Board）的领先指标指数在3月份下降0.6%，此前2月份曾上涨0.3%。世界大型企业联合会表示，领先指标指数表明，由于油价上涨和供应链问题，未来几个月美国经济可能进一步走弱。 截至 4 月 24 日当周，天然气库存增加 790 亿立方英尺，达到 2.142 万亿立方英尺，比上年同期增长 5.7%，比过去五年同期季节性平均水平高出 7.7%。
Related Articles
Mining & Metals
Agnico Eagle Q1 Record Adjusted Net Income of U$1,706 million or $3.41 per share
$AEM.TO
Treasury
TD Bank Group Issues 150 Million Swiss francs Green Bond
Toronto-Dominion Bank (TD.TO) after the close Thursday said it issued its seventh sustainable-labelled bonds for 150-million Swiss francs. The bank said its total sustainable bond issuances have now exceeded C$5.2 billion since 2014."TD's first European green bond continues building the strength of our sustainable financing program, helping us support clients pursuing sustainable investment in a new jurisdiction," said Nicole Vadori, head of sustainability at TD.TD shares closed up $3.40 at $146.33 on Toronto Stock Exchange.
$TD$TD.TO
Research
Research Alert: Amgn Q1 Tops Estimates Driven By Diversified Growth And Pipeline Investments
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.
$AMGN